Novo Nordisk A/S (NVO) Shares Sold by Sunbelt Securities Inc.

Sunbelt Securities Inc. trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,029 shares of the company’s stock after selling 116 shares during the quarter. Novo Nordisk A/S comprises approximately 1.3% of Sunbelt Securities Inc.’s portfolio, making the stock its 19th biggest position. Sunbelt Securities Inc.’s holdings in Novo Nordisk A/S were worth $687,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Proficio Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock valued at $103,000 after purchasing an additional 1,505 shares in the last quarter. AlphaMark Advisors LLC boosted its holdings in Novo Nordisk A/S by 1.1% in the second quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock valued at $113,000 after purchasing an additional 30 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock valued at $117,000 after purchasing an additional 1,553 shares in the last quarter. MUFG Americas Holdings Corp boosted its holdings in Novo Nordisk A/S by 100.0% in the second quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock valued at $129,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock valued at $105,000 after purchasing an additional 1,918 shares in the last quarter. 6.01% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Novo Nordisk A/S (NVO) Shares Sold by Sunbelt Securities Inc.” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.com-unik.info/2017/10/12/novo-nordisk-as-nvo-shares-sold-by-sunbelt-securities-inc.html.

Shares of Novo Nordisk A/S (NVO) traded down 0.391% during midday trading on Thursday, reaching $49.187. The company’s stock had a trading volume of 4,854,840 shares. The company’s 50-day moving average price is $48.14 and its 200 day moving average price is $42.82. The firm has a market capitalization of $121.99 billion, a PE ratio of 19.786 and a beta of 0.61. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $49.50.

NVO has been the subject of a number of research analyst reports. BidaskClub raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, June 15th. Zacks Investment Research downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Bank of America Corporation upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, September 6th. Finally, BNP Paribas cut Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $55.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

What are top analysts saying about Novo Nordisk A/S? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novo Nordisk A/S and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit